• Contact quintiles

    Phone:+1 866 267 4479

    Request a Proposal

  • Safety and Pharmacovigilance

  • clinical-trials-header
  • Quintiles Clinical Trial

    While the Biopharma market continues to face increased regulatory and cost pressures, patient safety remains top priority.

    At Quintiles, our Lifecycle Safety organization has evolved with the changing safety, regulatory, and development landscape to help meet new Pharmacovigilance needs across the lifecycle from clinical through post-approval.

    Transform pharmacovigilance compliance into a competitive advantage with Lifecycle Safety.

    Capture Process Efficiencies: Between March 2011 and March 2012, our team processed 267K+ safety cases with 99% on time, and reported 59K+ cases to regulatory authorities with 99.8% on-time compliance. Learn more about the processes, expertise and technology that help us deliver high quality, timely, safety reports:

    Meet PV Regulatory Expectations: At Quintiles, former regulatory agency staff and Qualified Persons for Pharmacovigilance (QPPVs) can help you manage changing global regulations and post-approval safety deliverables while gaining a deeper understanding of your benefit-risk profile. Learn more:

    The result? Bring together regulatory insights and PV process expertise to deliver high quality, timely, safety and regulatory reports, ultimately saving time and costs.

  • Lifecycle safety insights for proactive benefit-risk management

  • Quintiles Clinical Trails

    Deirdre McCarthy, Director of Customer Delivery with Quintiles, based in Dublin, Ireland discusses the top 5 areas of focus as you update your PV system to become compliant under the new EU Pharmacovigilance requirements.  Learn More

  • Quintiles Clinical Trails

    In this excerpt from our full webinar “Adjusting Effectively to Meeting New European Union Pharmacovigilance Requirements,” Deirdre McCarthy will provide a summary of some of the major changes to the Periodic Safety Update Reports (PSUR) format as a result of the new regulations.
    Learn More